Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.

A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days. Urinary tract infection was defined as pyuria and bacteriuria (cfu > or = 10(5)/mL). Evaluations were performed at four time-points. The clinical efficacy of the two antibacterial agents was equivalent at the end of treatment: clinical cure in 88.6% of the intent-to-treat population and 87.3% in the evaluable population treated with sparfloxacin compared to 85.4% and 84.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The clinical results were also equivalent at follow-up. The bacteriological efficacy of the two agents was not equivalent. At the end of treatment, bacteriological cure was observed in 72.6% of the intent-to-treat and 72.1% of the evaluable populations treated with sparfloxacin and in 81.4% and 80.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The difference was primarily because of a higher number of persisting pathogens, which included Enterobacteriaceae other than Escherichia coli, Pseudomonas aeruginosa and enterococci, which exhibited moderate susceptibility to sparfloxacin. Tolerability was similar in the two treatment groups.

[1]  Y. Kawada Criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection. , 2000, The Japanese journal of antibiotics.

[2]  J. Vercken,et al.  Study design, methodology and statistical analyses in the clinical development of sparfloxacin. , 1996, The Journal of antimicrobial chemotherapy.

[3]  J. Shimada,et al.  Clinical Pharmacokinetics of Sparfloxacin , 1993, Clinical pharmacokinetics.

[4]  D. Gilbert,et al.  European guidelines for anti-infective drug products. Introduction. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Davis,et al.  Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Neu,et al.  In vitro activity of sparfloxacin , 1991, Antimicrobial Agents and Chemotherapy.

[7]  K. Naber Use of quinolones in urinary tract infections and prostatitis. , 1989, Reviews of infectious diseases.

[8]  W. Stamm Criteria for the diagnosis of urinary tract infection and for the assessment of therapeutic effectiveness , 1992, Infection.

[9]  K. Naber,et al.  Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects. , 1987, Scandinavian journal of urology and nephrology. Supplementum.